{
    "id": 13862,
    "fullName": "KMT2A rearrange",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "KMT2A rearrangement indicates an unspecified rearrangement of the KMT2A gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 4297,
        "geneSymbol": "KMT2A",
        "terms": [
            "KMT2A",
            "ALL-1",
            "CXXC7",
            "HRX",
            "HTRX1",
            "MLL",
            "MLL1",
            "MLL1A",
            "TRX1",
            "WDSTS"
        ]
    },
    "variant": "rearrange",
    "createDate": "11/10/2015",
    "updateDate": "09/17/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9497,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Istodax (romidepsin) resulted in minimal activity in acute lymphocytic leukemia cell lines harboring a KMT2A rearrangement in culture, and in cell line xenograft models, demonstrating decreased leukemic cells by 16% (PMID: 27443263).",
            "molecularProfile": {
                "id": 14079,
                "profileName": "KMT2A rearrange"
            },
            "therapy": {
                "id": 1075,
                "therapyName": "Romidepsin",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7225,
                    "pubMedId": 27443263,
                    "title": "Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27443263"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3776,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, I-CBP112 sensitized leukemia cells harboring KMT2A fusions to JQ1, resulting in decreased cell growth in culture (PMID: 26552700).",
            "molecularProfile": {
                "id": 14079,
                "profileName": "KMT2A rearrange"
            },
            "therapy": {
                "id": 3298,
                "therapyName": "I-CBP112 + JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4120,
                    "pubMedId": 26552700,
                    "title": "Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26552700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16352,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-539 inhibited growth of KMT2A (MLL1)-rearranged acute myeloid leukemia cells in culture, and prolonged survival in cell-line xenograft models (AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-A27).",
            "molecularProfile": {
                "id": 14079,
                "profileName": "KMT2A rearrange"
            },
            "therapy": {
                "id": 8006,
                "therapyName": "KO-539",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14464,
                    "pubMedId": null,
                    "title": "A novel small molecule menin-MLL inhibitor for potential treatment of MLL-rearranged leukemias and NPM1/DNMT3A-mutant AML",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/LB-A27"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9498,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cytosar-U (cytarabine) decreased leukemic cells by 66% in acute lymphocytic leukemia cell line xenograft models harboring a KMT2A rearrangement (PMID: 27443263).",
            "molecularProfile": {
                "id": 14079,
                "profileName": "KMT2A rearrange"
            },
            "therapy": {
                "id": 712,
                "therapyName": "Cytarabine",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7225,
                    "pubMedId": 27443263,
                    "title": "Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27443263"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9495,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Istodax (romidepsin) enhanced the effects of Cytosar-U (cytarabine) in acute lymphocytic leukemia cell lines harboring a KMT2A rearrangement in culture, and in cell line xenograft models, demonstrating decreased leukemic cells by 73% (PMID: 27443263).",
            "molecularProfile": {
                "id": 14079,
                "profileName": "KMT2A rearrange"
            },
            "therapy": {
                "id": 5035,
                "therapyName": "Cytarabine + Romidepsin",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7225,
                    "pubMedId": 27443263,
                    "title": "Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27443263"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16656,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Pinometostat (EPZ-5676) treatment resulted in complete remission in 2 patients with KMT2A rearranged (both with t(11;19)) acute leukemia (PMID: 29724899; NCT01684150).",
            "molecularProfile": {
                "id": 14079,
                "profileName": "KMT2A rearrange"
            },
            "therapy": {
                "id": 2855,
                "therapyName": "Pinometostat",
                "synonyms": null
            },
            "indication": {
                "id": 12603,
                "name": "acute leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14705,
                    "pubMedId": 29724899,
                    "title": "The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29724899"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9491,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Farydak (panobinostat) enhanced the effects of Cytosar-U (cytarabine) in acute lymphoblastic leukemia cells harboring a KMT2A rearrangement in culture, resulting in cell death (PMID: 27443263).",
            "molecularProfile": {
                "id": 14079,
                "profileName": "KMT2A rearrange"
            },
            "therapy": {
                "id": 5036,
                "therapyName": "Cytarabine + Panobinostat",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7225,
                    "pubMedId": 27443263,
                    "title": "Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27443263"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9492,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mocetinostat (MGCD0103) enhanced the effects of Cytosar-U (cytarabine) in acute lymphoblastic leukemia cell lines harboring a KMT2A rearrangement in culture, resulting in cell death (PMID: 27443263).",
            "molecularProfile": {
                "id": 14079,
                "profileName": "KMT2A rearrange"
            },
            "therapy": {
                "id": 5037,
                "therapyName": "Cytarabine + Mocetinostat",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7225,
                    "pubMedId": 27443263,
                    "title": "Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27443263"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3775,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, I-CBP112 sensitized leukemia cells harboring KMT2A fusions to Doxorubicin, leading to decreased cell growth in culture (PMID: 26552700).",
            "molecularProfile": {
                "id": 14079,
                "profileName": "KMT2A rearrange"
            },
            "therapy": {
                "id": 3299,
                "therapyName": "Doxorubicin + I-CBP112",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4120,
                    "pubMedId": 26552700,
                    "title": "Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26552700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9493,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Dacinostat (LAQ824) enhanced the effects of Cytosar-U (cytarabine) in acute lymphoblastic leukemia cell lines harboring a KMT2A rearrangement in culture, resulting in cell death (PMID: 27443263).",
            "molecularProfile": {
                "id": 14079,
                "profileName": "KMT2A rearrange"
            },
            "therapy": {
                "id": 5038,
                "therapyName": "Cytarabine + Dacinostat",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7225,
                    "pubMedId": 27443263,
                    "title": "Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27443263"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6222,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "In multiple clinical studies, KMT2A rearrangements, specifically partial tandem duplications, were associated with a poor overall survival in acute myeloid leukemia patients (PMID: 24487413, PMID: 22915647, PMID: 22417203, PMID: 21881046).",
            "molecularProfile": {
                "id": 14079,
                "profileName": "KMT2A rearrange"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5338,
                    "pubMedId": 22915647,
                    "title": "A novel hierarchical prognostic model of AML solely based on molecular mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22915647"
                },
                {
                    "id": 5346,
                    "pubMedId": 21881046,
                    "title": "Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21881046"
                },
                {
                    "id": 5477,
                    "pubMedId": 24487413,
                    "title": "Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24487413"
                },
                {
                    "id": 5478,
                    "pubMedId": 22417203,
                    "title": "Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22417203"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18088,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "KMT2A rearrangements (t(v;11q23.3)) are associated with a poor/adverse prognosis in patients with non-APL acute myeloid leukemia (NCCN.org).",
            "molecularProfile": {
                "id": 14079,
                "profileName": "KMT2A rearrange"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 14079,
            "profileName": "KMT2A rearrange",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}